The aim of this study was to review the extent of drug use for unlicensed purposes in a palliative care unit. We carried out a prospective study of all patients with advanced malignancy admitted to a 10-bed specialist palliative care unit over a 4-month period. Prescriptions were assessed and compared with licensed prescribing indications. Seventy-six patients were included in the study; 689 prescriptions were made using 84 drugs to treat 34 different symptoms. Fifteen per cent of prescribing events were for unlicensed indications. We conclude that drugs are frequently used in the palliative care setting for purposes unsupported by product licences, although usually backed by literature. These drugs are often prescribed for symptoms which are difficult to control.
Anon. Prescribing unlicensed drugs or using drugs for unlicensed indications. DTB1992; 30: 97–99.
2.
Anon. How drugs get to market. DTB1990: 28: 101–104.
3.
Roy DJ, MacDonald N. Ethical issues in palliative care. In: Calman K, Hanks GWC, MacDonald N, eds. Oxford textbook of palliative medicine, 2nd edn.Oxford: Oxford University Press, 1998: 103–107.
4.
ABPI data sheet compendium 1996–97. London: Datapharm Publications, 1996.
Tobin MJ. Dyspnea. Pathophysiologic basis, clinical presentation and management. Arch Intern Med1990; 150: 1604–1613.
7.
Young IH, Daviskas E, Keena VA. Effect of low-dose nebulized morphine on exercise endurance in patients with chronic lung disease. Thorax1989; 44: 387–390.
8.
MacKay C, Murray WR, Sali A. Aluminium hydroxide in bile-salt diarrhoea. Lancet1977; ii: 1051–1053.
9.
Burgstaler EA, Carlson GL, Dickson ER, Lauterburg BH, Pineda AA, Taswell HF. Treatment of pruritis of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet1980; ii: 53–55.
10.
Twycross R, Lichter I. The terminal phase. In: Calman K, Hanks GWC, MacDonald N eds. Oxford textbook of palliative medicine, 2nd edn.Oxford: Oxford University Press, 1998: 160–162.
11.
Roberts CJC, Keir S, Hanks GWC. The principles of drug use in palliative medicine. In: Calman K, Hanks GWC, MacDonald N eds. Oxford textbook of palliative medicine, 2nd edn.Oxford: Oxford University Press, 1998: 227–231.
12.
Doyle D. Domiciliary palliative care. In: Calman K, Hanks GWC, MacDonald N eds. Oxford textbook of palliative medicine, 2nd edn.Oxford: Oxford University Press, 1998: 957–973.
13.
Thirlby RC. Toward a treatment for anorexia and cachexia in patients with cancer. Gastroenterology1991; 101: 268–270.
14.
Sykes NP, Baines M, Carter RL. Clinical and pathological study of dysphagia conservatively managed in patients with advanced malignant disease. Lancet1988; ii: 726–728.
15.
Rousseau P. Non-pain symptom management in terminal care. Clin Geriatr Med1996; 12: 313–317.
16.
Mercadante S, Kargar J, Nicolosi G. Octreotide may prevent definitive intestinal obstruction. J Pain Symptom Manage1997; 13: 352–355.
17.
Hanks GW. Opioid-responsive and opioid-non-responsive pain in cancer. Br Med Bull1991; 47: 718–731.
18.
Walsh TD, West TS. Controlling symptoms in advanced cancer. Br Med J1988; 296: 477–481.
19.
Wells JCD, Miles JB. Pain clinics and pain clinic treatments. Br Med Bull1991; 47: 762–785.
20.
Richter JE, Bradley LA, Castell DO. Esophageal chest pain: current contraversies in pathogenesis, diagnosis, and therapy. Ann Intern Med1989; 110: 66–78.
21.
Ahmedzai S. Palliation of respiratory symptoms. In: Calman K, Hanks GWC, MacDonald N eds. Oxford textbook of palliative medicine, 2nd edn.Oxford: Oxford University Press, 1998: 586–604.
22.
Fox PC, Atkinson JC, Macynski AA et al. Pilocarpine in the treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med1991; 151: 1149–1152.
23.
Bennett MI. Death rattle: an audit of hyoscine (scopalamine) use and review of management. J Pain Symptom Manage1996; 12: 229–233.
24.
Nubiola-Calonge P, Badia JM, Gil MJ, Sancho J, Segura M, Sitges-Serra A. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output. Lancet1987; ii: 672–673.
25.
Khoo D, Riley J, Waxman J. Control of emesis in bowel obstruction in terminally ill patients. Lancet1992; 339: 375–376.
26.
Mangili G, Franchi M, Mariani A et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynaecol Oncol1996; 61: 345–348.
27.
Lund JN, Scholefield JH. A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure. Lancet1997; 349: 11–14.
